Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

Annals of Neurology

Volumn 48, Issue 5, 2000, Pages 706-712

  Ross, Christian ^a   Clemmesen, Katja Maria ^a   Svenson, Morten ^a   Srensen, Per Soelberg ^b   Koch Henriksen, Nils ^c   Skovgaard, Gunhild Lange ^a   Bendtzen, Klaus ^a,b  

^a Institute for Inflammation Research   (Denmark)

^b University of Copenhagen   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; RECOMBINANT BETA INTERFERON;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; IMMUNOGENICITY; INTERFERON INDUCTION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE;

ADOLESCENT; ADULT; BINDING SITES, ANTIBODY; DENMARK; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0033763507     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.0.CO;2-V     Document Type: Article

References (24)

1. Interferon β-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
2. Interferon β-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
4. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
5. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
6. Immunologic therapy of multiple sclerosis
7. High-avidity autoantibodies to cytokines
8. Clinical significance of anti-IFN-α antibody titres during interferon therapy
9. Resistance to recombinant interferon α-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
10. Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C virus infection
11. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
12. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
13. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy
14. Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: Experience during the first three years
15. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells
16. Neutralising and binding anti-interferon-β-1b (IFN-β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis
17. Treatment of multiple sclerosis with interferon β-1b
18. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG
19. The expression of potency of neutralizing antibodies for interferons and other cytokines
20. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
21. In vivo development of antibody to interferons: An update to 1996
22. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a
23. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive
24. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b